AU2019227823B2 - WEE1 kinase inhibitors and methods of treating cancer using the same - Google Patents

WEE1 kinase inhibitors and methods of treating cancer using the same Download PDF

Info

Publication number
AU2019227823B2
AU2019227823B2 AU2019227823A AU2019227823A AU2019227823B2 AU 2019227823 B2 AU2019227823 B2 AU 2019227823B2 AU 2019227823 A AU2019227823 A AU 2019227823A AU 2019227823 A AU2019227823 A AU 2019227823A AU 2019227823 B2 AU2019227823 B2 AU 2019227823B2
Authority
AU
Australia
Prior art keywords
compound
mmol
cancer
wee1
mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019227823A
Other languages
English (en)
Other versions
AU2019227823A1 (en
Inventor
Donald S. BACKOS
Kimberly A. CASALVIERI
Christopher J. MATHESON
Philip Reigan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Colorado Springs
Original Assignee
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System, University of Colorado Colorado Springs filed Critical University of Colorado System
Publication of AU2019227823A1 publication Critical patent/AU2019227823A1/en
Application granted granted Critical
Publication of AU2019227823B2 publication Critical patent/AU2019227823B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019227823A 2018-02-28 2019-02-28 WEE1 kinase inhibitors and methods of treating cancer using the same Active AU2019227823B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636831P 2018-02-28 2018-02-28
US62/636,831 2018-02-28
PCT/US2019/019936 WO2019169065A2 (en) 2018-02-28 2019-02-28 Wee1 kinase inhibitors and methods of treating cancer using the same

Publications (2)

Publication Number Publication Date
AU2019227823A1 AU2019227823A1 (en) 2020-08-06
AU2019227823B2 true AU2019227823B2 (en) 2024-12-12

Family

ID=67805580

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019227823A Active AU2019227823B2 (en) 2018-02-28 2019-02-28 WEE1 kinase inhibitors and methods of treating cancer using the same

Country Status (6)

Country Link
US (2) US12220415B2 (enExample)
EP (1) EP3758706A4 (enExample)
JP (1) JP7483620B2 (enExample)
AU (1) AU2019227823B2 (enExample)
CA (1) CA3088997A1 (enExample)
WO (1) WO2019169065A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016344040B2 (en) 2015-11-01 2020-12-10 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2020527588A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． アデノシンアンタゴニストとしてのヘテロ環式化合物
CA3078945A1 (en) 2017-10-09 2019-04-18 Nuvation Bo Inc. Heterocyclic compounds and uses thereof
EP3694861A4 (en) 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
CA3088997A1 (en) 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
BR112020018286A2 (pt) 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
WO2020150674A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
JP2022526831A (ja) 2019-04-09 2022-05-26 ニューベイション・バイオ・インコーポレイテッド ヘテロ環式化合物およびその使用
CN115023229A (zh) * 2019-12-20 2022-09-06 里科瑞尔姆Ip控股有限责任公司 组合
BR112022012283A2 (pt) * 2019-12-20 2022-08-30 Recurium Ip Holdings Llc Combinações
CN113402520A (zh) * 2020-03-16 2021-09-17 中国科学院上海药物研究所 Wee1蛋白降解剂
AU2021290701A1 (en) * 2020-06-17 2023-02-02 Wigen Biomedicine Technology (shanghai) Co., Ltd. Pyrazolo(3,4-d)pyrimidine-3-ketone derivative as Wee-1 inhibitor
JP7866564B2 (ja) * 2021-05-28 2026-05-27 江蘇天士力帝益薬業有限公司 Ｗｅｅ１阻害剤とその用途
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254892A1 (en) * 2006-04-27 2007-11-01 Takeshi Sagara Dihydropyrazolopyrimidinone derivatives
WO2017075629A2 (en) * 2015-11-01 2017-05-04 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
WO2019028008A1 (en) * 2017-08-01 2019-02-07 Zeno Royalties & Milestones, LLC 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB884151A (en) 1957-12-06 1961-12-06 Ciba Ltd New pyrazolo-pyrimidines substituted in the pyrazole nucleus, and process for their manufacture
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
RU2011141121A (ru) * 2009-03-11 2013-04-20 Окленд Юнисервисиз Лимитед Пролекарственные формы ингибиторов киназ и их применение в терапии
BR112012004720B1 (pt) 2009-09-02 2021-06-29 Auckland Uniservices Limited Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
AU2018209006B2 (en) 2017-01-22 2021-04-22 Sunshine Lake Pharma Co., Ltd. Thienopyrimidine derivative and use thereof in medicine
JP6717457B2 (ja) 2017-01-23 2020-07-01 シージャーズォアン サガシティ ニュー ドラッグ デベロップメント カンパニー リミテッド Ｗｅｅ１阻害剤としての１，２−ジヒドロ−３Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−３−オン誘導体
CA3088997A1 (en) 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254892A1 (en) * 2006-04-27 2007-11-01 Takeshi Sagara Dihydropyrazolopyrimidinone derivatives
WO2007126122A1 (en) * 2006-04-27 2007-11-08 Banyu Pharmaceutical Co., Ltd. Dihydropyrazolopyrimidinone derivatives
US8791125B2 (en) * 2006-04-27 2014-07-29 Msd K.K. Dihydropyrazolopyrimidinone derivatives
WO2017075629A2 (en) * 2015-11-01 2017-05-04 The Regents Of The University Of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
WO2019028008A1 (en) * 2017-08-01 2019-02-07 Zeno Royalties & Milestones, LLC 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
O'CONNER, ET AL. vol. 2, 2015, pages 1-4, Retrieved from the Internet *

Also Published As

Publication number Publication date
US20200405723A1 (en) 2020-12-31
EP3758706A2 (en) 2021-01-06
JP2021516231A (ja) 2021-07-01
JP7483620B2 (ja) 2024-05-15
US12220415B2 (en) 2025-02-11
AU2019227823A1 (en) 2020-08-06
EP3758706A4 (en) 2021-11-24
US20250186447A1 (en) 2025-06-12
WO2019169065A2 (en) 2019-09-06
WO2019169065A3 (en) 2020-04-30
CA3088997A1 (en) 2019-09-06

Similar Documents

Publication Publication Date Title
US20250186447A1 (en) Wee1 kinase inhibitors and methods of treating cancer using the same
EP3368538B1 (en) Wee 1 kinase inhibitors and methods of making and using the same
US11952380B2 (en) Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors
WO2021121367A1 (en) Kras mutant protein inhibitors
KR101268354B1 (ko) 사이클릭 아닐리노-피리디노트리아진
US10703759B2 (en) 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
EP3497103A1 (en) Pyridopyrimdinone cdk2/4/6 inhibitors
JP7839786B2 (ja) 新規アミノピリジン及びその癌治療への使用
EP3284746B1 (en) Preparation and use of kinase inhibitor
PH12015502737B1 (en) Novel fused pyrimidine compound or salt thereof
EP4011885A1 (en) Oxo-pyridine fusion ring derivative and pharmaceutical composition comprising same
CA2984496A1 (en) Bicyclic compounds
CN115677730B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
KR20260020414A (ko) 화학적 화합물 및 그의 용도
EP4741379A1 (en) Class of programmed cell death inhibitors, preparation method therefor and use thereof
EP3440070B1 (en) Mdr-reversing 8-hydroxy-quinoline derivatives
EP3242881B1 (en) Furoquinolinediones as inhibitors of tdp2
WO2013055771A1 (en) Thioxothiazolidinone derivatives useful as inhibitors of tdp1
CN120574234A (zh) 具有透脑功能的高选择性parp1抑制剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)